Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: HERPUD1

Gene summary for HERPUD1

Gene summary.

Gene information	Species	Human
	Gene symbol	HERPUD1
	Gene ID	9709
	Gene name	homocysteine inducible ER protein with ubiquitin like domain 1
	Gene Alias	HERP
	Cytomap	16q13
	Gene Type	protein-coding
	GO ID	GO:0006464
	UniProtAcc	Q15011

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9709	HERPUD1	GSM4909286	Human	Breast	IDC	5.17e-16	-5.31e-01	0.1081
9709	HERPUD1	GSM4909294	Human	Breast	IDC	2.77e-04	-3.91e-01	0.2022
9709	HERPUD1	GSM4909296	Human	Breast	IDC	1.01e-18	-5.23e-01	0.1524
9709	HERPUD1	GSM4909297	Human	Breast	IDC	5.30e-13	-1.87e-01	0.1517
9709	HERPUD1	GSM4909301	Human	Breast	IDC	3.70e-08	-4.02e-01	0.1577
9709	HERPUD1	GSM4909302	Human	Breast	IDC	7.51e-14	-5.30e-01	0.1545
9709	HERPUD1	GSM4909304	Human	Breast	IDC	6.31e-03	-3.33e-01	0.1636
9709	HERPUD1	GSM4909307	Human	Breast	IDC	1.55e-13	-5.05e-01	0.1569
9709	HERPUD1	GSM4909308	Human	Breast	IDC	2.95e-04	-3.58e-01	0.158
9709	HERPUD1	GSM4909309	Human	Breast	IDC	9.60e-05	-3.90e-01	0.0483
9709	HERPUD1	GSM4909311	Human	Breast	IDC	4.78e-31	-5.15e-01	0.1534
9709	HERPUD1	GSM4909312	Human	Breast	IDC	5.72e-09	-6.08e-02	0.1552
9709	HERPUD1	GSM4909319	Human	Breast	IDC	8.85e-42	-5.16e-01	0.1563
9709	HERPUD1	GSM4909320	Human	Breast	IDC	5.15e-05	-5.17e-01	0.1575
9709	HERPUD1	GSM4909321	Human	Breast	IDC	1.60e-13	-2.32e-01	0.1559
9709	HERPUD1	M1	Human	Breast	IDC	1.16e-03	-3.91e-01	0.1577
9709	HERPUD1	NCCBC14	Human	Breast	DCIS	2.30e-10	-2.08e-01	0.2021
9709	HERPUD1	NCCBC2	Human	Breast	DCIS	1.48e-02	-3.51e-01	0.1554
9709	HERPUD1	NCCBC3	Human	Breast	DCIS	1.95e-07	2.88e-01	0.1198
9709	HERPUD1	NCCBC5	Human	Breast	DCIS	5.20e-16	-3.68e-01	0.2046

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:200123314	Breast	IDC	regulation of apoptotic signaling pathway	82/1434	356/18723	6.27e-20	5.93e-17	82
GO:005254714	Breast	IDC	regulation of peptidase activity	96/1434	461/18723	7.58e-20	6.15e-17	96
GO:009719314	Breast	IDC	intrinsic apoptotic signaling pathway	69/1434	288/18723	6.32e-18	2.99e-15	69
GO:005254814	Breast	IDC	regulation of endopeptidase activity	88/1434	432/18723	1.20e-17	4.85e-15	88
GO:200124214	Breast	IDC	regulation of intrinsic apoptotic signaling pathway	47/1434	164/18723	8.25e-16	2.93e-13	47
GO:200011614	Breast	IDC	regulation of cysteine-type endopeptidase activity	55/1434	235/18723	4.25e-14	1.21e-11	55
GO:004586114	Breast	IDC	negative regulation of proteolysis	70/1434	351/18723	8.21e-14	2.22e-11	70
GO:004328114	Breast	IDC	regulation of cysteine-type endopeptidase activity involved in apoptotic process	50/1434	209/18723	2.49e-13	6.14e-11	50
GO:005134613	Breast	IDC	negative regulation of hydrolase activity	71/1434	379/18723	1.33e-12	2.90e-10	71
GO:001046613	Breast	IDC	negative regulation of peptidase activity	56/1434	262/18723	1.39e-12	2.92e-10	56
GO:200123414	Breast	IDC	negative regulation of apoptotic signaling pathway	49/1434	224/18723	1.45e-11	2.58e-09	49
GO:001095112	Breast	IDC	negative regulation of endopeptidase activity	52/1434	252/18723	3.53e-11	5.57e-09	52
GO:004586214	Breast	IDC	positive regulation of proteolysis	66/1434	372/18723	9.76e-11	1.29e-08	66
GO:200124314	Breast	IDC	negative regulation of intrinsic apoptotic signaling pathway	27/1434	98/18723	2.91e-09	2.50e-07	27
GO:200011713	Breast	IDC	negative regulation of cysteine-type endopeptidase activity	25/1434	86/18723	3.31e-09	2.77e-07	25
GO:001049814	Breast	IDC	proteasomal protein catabolic process	75/1434	490/18723	5.59e-09	4.41e-07	75
GO:004217614	Breast	IDC	regulation of protein catabolic process	63/1434	391/18723	1.32e-08	9.61e-07	63
GO:190336214	Breast	IDC	regulation of cellular protein catabolic process	46/1434	255/18723	4.00e-08	2.68e-06	46
GO:004315413	Breast	IDC	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	22/1434	78/18723	5.26e-08	3.32e-06	22
GO:190305014	Breast	IDC	regulation of proteolysis involved in cellular protein catabolic process	41/1434	221/18723	9.77e-08	5.84e-06	41

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0414124	Breast	IDC	Protein processing in endoplasmic reticulum	36/867	174/8465	2.73e-05	2.86e-04	2.14e-04	36
hsa0414134	Breast	IDC	Protein processing in endoplasmic reticulum	36/867	174/8465	2.73e-05	2.86e-04	2.14e-04	36
hsa0414143	Breast	DCIS	Protein processing in endoplasmic reticulum	36/846	174/8465	1.60e-05	1.91e-04	1.41e-04	36
hsa0414153	Breast	DCIS	Protein processing in endoplasmic reticulum	36/846	174/8465	1.60e-05	1.91e-04	1.41e-04	36
hsa0414120	Cervix	CC	Protein processing in endoplasmic reticulum	55/1267	174/8465	1.74e-08	2.68e-07	1.58e-07	55
hsa04141110	Cervix	CC	Protein processing in endoplasmic reticulum	55/1267	174/8465	1.74e-08	2.68e-07	1.58e-07	55
hsa0414125	Cervix	HSIL_HPV	Protein processing in endoplasmic reticulum	21/459	174/8465	4.54e-04	3.80e-03	3.07e-03	21
hsa0414135	Cervix	HSIL_HPV	Protein processing in endoplasmic reticulum	21/459	174/8465	4.54e-04	3.80e-03	3.07e-03	21
hsa0414144	Cervix	N_HPV	Protein processing in endoplasmic reticulum	21/349	174/8465	8.84e-06	1.09e-04	8.55e-05	21
hsa0414154	Cervix	N_HPV	Protein processing in endoplasmic reticulum	21/349	174/8465	8.84e-06	1.09e-04	8.55e-05	21
hsa04141	Colorectum	AD	Protein processing in endoplasmic reticulum	80/2092	174/8465	5.96e-10	1.25e-08	7.96e-09	80
hsa041411	Colorectum	AD	Protein processing in endoplasmic reticulum	80/2092	174/8465	5.96e-10	1.25e-08	7.96e-09	80
hsa041412	Colorectum	SER	Protein processing in endoplasmic reticulum	60/1580	174/8465	4.20e-07	7.33e-06	5.32e-06	60
hsa041413	Colorectum	SER	Protein processing in endoplasmic reticulum	60/1580	174/8465	4.20e-07	7.33e-06	5.32e-06	60
hsa041414	Colorectum	MSS	Protein processing in endoplasmic reticulum	75/1875	174/8465	3.78e-10	8.44e-09	5.17e-09	75
hsa041415	Colorectum	MSS	Protein processing in endoplasmic reticulum	75/1875	174/8465	3.78e-10	8.44e-09	5.17e-09	75
hsa041416	Colorectum	MSI-H	Protein processing in endoplasmic reticulum	46/797	174/8465	4.53e-11	9.78e-10	8.19e-10	46
hsa041417	Colorectum	MSI-H	Protein processing in endoplasmic reticulum	46/797	174/8465	4.53e-11	9.78e-10	8.19e-10	46
hsa0414127	Endometrium	EEC	Protein processing in endoplasmic reticulum	64/1237	174/8465	2.17e-13	5.09e-12	3.80e-12	64
hsa0414136	Endometrium	EEC	Protein processing in endoplasmic reticulum	64/1237	174/8465	2.17e-13	5.09e-12	3.80e-12	64

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

HERPUD1

SNV

Missense_Mutation

rs370880807

c.1168G>A

p.Ala390Thr

p.A390T

Q15011

protein_coding

tolerated(0.08)

benign(0.17)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HERPUD1

SNV

Missense_Mutation

rs527424441

c.394N>T

p.Arg132Trp

p.R132W

Q15011

protein_coding

tolerated(0.17)

benign(0.2)

TCGA-E2-A14S-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

HERPUD1

insertion

Frame_Shift_Ins

novel

c.1064_1065insTC

p.Val356LeufsTer3

p.V356Lfs*3

Q15011

protein_coding

TCGA-A2-A0CX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

HERPUD1

insertion

In_Frame_Ins

novel

c.1066_1067insTAACAGTGTGTTATACCATAAGAACTGGTATGAAGTGGT

p.Val356_Leu357insThrValCysTyrThrIleArgThrGlyMetLysTrpLeu

p.V356_L357insTVCYTIRTGMKWL

Q15011

protein_coding

TCGA-A2-A0CX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

HERPUD1

insertion

Nonsense_Mutation

novel

c.1155_1156insAATAAATTAGGAACCTCTTGAATTAT

p.Pro386AsnfsTer7

p.P386Nfs*7

Q15011

protein_coding

TCGA-AN-A0FX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

HERPUD1

insertion

Nonsense_Mutation

novel

c.879_880insTAAAATCTCCTTCATGAGATTGCTGTGGACCCAGCAGCCTGTACAGG

p.Met294Ter

p.M294*

Q15011

protein_coding

TCGA-AO-A0JB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

HERPUD1

deletion

Frame_Shift_Del

novel

c.823delT

p.Ser275LeufsTer13

p.S275Lfs*13

Q15011

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

HERPUD1

SNV

Missense_Mutation

novel

c.950A>C

p.Asn317Thr

p.N317T

Q15011

protein_coding

tolerated(0.17)

benign(0.096)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

HERPUD1

SNV

Missense_Mutation

c.916G>T

p.Gly306Trp

p.G306W

Q15011

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-C5-A2LX-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

HERPUD1

SNV

Missense_Mutation

c.886N>A

p.Ala296Thr

p.A296T

Q15011

protein_coding

deleterious(0.05)

possibly_damaging(0.86)

TCGA-AA-3715-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1